Facebook picto   picto linkdink   picto tiwter


Oct 21, 2014
EDAP Announces Sale of Focal One Nantes

EDAP Announces Sale of Focal One(R) HIFU Device to Nantes-Atlantis Urology Clinic in France
Increasing Adoption of HIFU Focal in Leading French Robotic Prostate Cancer Centers

EDAP TMS SA, today announced the sale of a Focal One system to Nantes-Atlantis urology clinic, the top-ranked private prostate cancer clinic in France, and the country's only private clinic exclusively dedicated to urology.

Nantes-Atlantis Urology clinic is led by five renowned experts in urology, and offers the latest innovative technologies to patients suffering from urological diseases. The clinic performs more than 5,000 urological procedures per year, including more than 1,000 prostate cancer treatments. Nantes-Atlantis urology clinic has been successfully using the Focal One system on a mobile, per-treatment basis since early 2014, with 110 focal treatments performed year-to-date. By using the system on a per-treatment basis, Nantes-Atlantis' clinical team was convinced of the superiority of the focal HIFU technology and its revolutionary IRM/ultrasound fusing imaging approach, which led to its decision to purchase the device.

Dr. Georges Le Coguic, Chairman of Nantes-Atlantis urology clinic and Dr. Eric Potiron, urological surgeon and focal therapy expert, commented: "We are pleased to add the Focal One system, a revolutionary tool for prostate cancer, to our facility's suite of offerings. This is a real complement to our armamentarium of innovative technologies addressing prostate cancer. With Focal One, Atlantis-Nantes urology clinic will continue to be at the forefront of innovative therapeutic solutions in the treatment of prostate cancer."

Pierre Reboul, Director of EDAP's French Business Unit, commented: "We are very proud that our Focal One HIFU device is being used in the Nantes-Atlantis clinic, France's number one ranked private prostate cancer center. This system sale speaks to the momentum we are building for Focal One at key sites in Europe, following our sale to the leading public prostate cancer center in France: Institut Mutualiste Monsouris, Paris. We believe that the use of our Focal One technology at two of France's major prostate cancer centers is clear evidence that focal HIFU is becoming a must-have complement to robotic prostate surgery."

Reboul continued: "With the new reimbursement policies for HIFU treatment currently being rolled out in France, and our ability to offer a complete range of HIFU products to address prostate cancer management strategies, we are well positioned to address the estimated 10,000 prostate cancer patients per year that could benefit from HIFU technology, as published by the 'Haute Autorité de Santé' (French Health Authority)."

Marc Oczachowski, EDAP's Chief Executive Officer, concluded, "We are successfully expanding the footprint of our Focal One technology in Europe with strong support from leading prostate cancer centers. We will look to continue building on this adoption trend as we further develop our presence in the market through what we believe is an ideal solution to the growing demand for focal HIFU technologies in the treatment of prostate cancer."